120 related articles for article (PubMed ID: 20660962)
1. Diagnostic relevance of circulating biomarkers in patients with lung cancer.
Molina R; Holdenrieder S; Auge JM; Schalhorn A; Hatz R; Stieber P
Cancer Biomark; 2010; 6(3-4):163-78. PubMed ID: 20660962
[TBL] [Abstract][Full Text] [Related]
2. Biological markers in lung cancer: A clinician's perspective.
Tufman A; Huber RM
Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
[TBL] [Abstract][Full Text] [Related]
3. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer.
Holdenrieder S; Nagel D; Stieber P
Cancer Biomark; 2010; 6(3-4):179-90. PubMed ID: 20660963
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.
Ma PC; Blaszkowsky L; Bharti A; Ladanyi A; Kraeft SK; Bruno A; Skarin AT; Chen LB; Salgia R
Anticancer Res; 2003; 23(1A):49-62. PubMed ID: 12683352
[TBL] [Abstract][Full Text] [Related]
5. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
6. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer.
Barak V; Holdenrieder S; Nisman B; Stieber P
Cancer Biomark; 2010; 6(3-4):191-6. PubMed ID: 20660964
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
8. Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels.
Schneider J
Cancer Biomark; 2010; 6(3-4):149-62. PubMed ID: 20660961
[TBL] [Abstract][Full Text] [Related]
9. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N
Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257
[TBL] [Abstract][Full Text] [Related]
10. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
12. Circulating apoptotic markers in the management of non-small cell lung cancer.
Holdenrieder S; Stieber P
Cancer Biomark; 2010; 6(3-4):197-210. PubMed ID: 20660965
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of tumor markers in the management of small cell lung cancer].
Ariyoshi Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
[TBL] [Abstract][Full Text] [Related]
14. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
15. Detection of lung cancer in silicosis patients using a tumor-marker panel.
Schneider J
Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
Bremnes RM; Sirera R; Camps C
Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
[TBL] [Abstract][Full Text] [Related]
18. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
Wu Y; Wu Y; Wang L; Qu L
Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
[TBL] [Abstract][Full Text] [Related]
19. Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.
Yamamoto O; Takahashi H; Hirasawa M; Chiba H; Shiratori M; Kuroki Y; Abe S
Respir Med; 2005 Sep; 99(9):1164-74. PubMed ID: 16085219
[TBL] [Abstract][Full Text] [Related]
20. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
